F. Hoffmann

发表

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

M. Scholz, D. Niederwieser, U. Platzbecker, 2022, Journal of Cancer Research and Clinical Oncology.

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

D. Niederwieser, T. Ittel, R. Naumann, 2004 .

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

D. Niederwieser, R. Rohrberg, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Tolerance to the antinociceptive effect of Crotalus durissus terrificus snake venom in mice is mediated by pharmacodynamic mechanisms.

S. Barros, Y. Cury, M. Bernardi, 2001, Toxicon : official journal of the International Society on Toxinology.

Lethal complications in 30 patients after allogeneic BMT (BMT) and autografted (ABMT) patients (1980-1986) examined by autopsy.

T. Friedrich, W. Pönisch, W. Püschel, 1989, Folia haematologica.

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)

M. Scholz, U. Platzbecker, S. Schwind, 2021, Journal of Cancer Research and Clinical Oncology.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

H. Goldschmidt, D. Niederwieser, R. Rohrberg, 2008, British journal of haematology.

Acute and late effects in the course of and after total body irradiation with following bone marrow transplantation in patients with different forms of leukaemia.

P. Feyer, W. Helbig, F. Hoffmann, 1989, Folia haematologica.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

D. Niederwieser, T. Lindner, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

G. Behre, D. Niederwieser, T. Lindner, 2014, Journal of Cancer Research and Clinical Oncology.

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

D. Niederwieser, S. Schwind, T. Lange, 2015, Journal of Cancer Research and Clinical Oncology.

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

M. Scholz, D. Niederwieser, U. Platzbecker, 2022, Journal of Cancer Research and Clinical Oncology.

Lung Density Changes Measured by Computed Tomography in Patients Receiving Total Body Irradiation and Bone Marrow Transplantation

M. Spengler, T. Friedrich, P. Feyer, 1992 .

Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

J. Beck, D. Niederwieser, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.